CPI connects the dots within the innovation ecosystem to make great ideas and inventions a reality
We’re a pioneering social enterprise that accelerates the development, scale-up and commercialisation of deep tech and sustainable manufacturing solutions.
Alongside partners in industry, government and academia, CPI has created the Medicines Manufacturing Innovation Centre to develop, prove and commercialise disruptive technologies for the pharmaceutical industry. We operate a model focused on Grand Challenges where the pharmaceutical industry and its supply chain identify and overcome major industry hurdles to reduce the time, resources and cost of medicines manufacturing to ultimately deliver benefits to patients.
Now with over 30 organisations as partners, we continue to expand our Grand Challenge portfolio with projects identified by industry consortia.
Grand Challenge 1
Grand Challenge 1 is redefining how we produce oral solid dosage medicines more efficiently using continuous direct compression (CDC) and has created a world-class demonstrator to prove CDC principles. It will accelerate the industry’s adoption of streamlined, agile formulation technologies and digital twins to reduce the development burden, cost to patients and carbon footprint of production.
Grand Challenge 2
Grand Challenge 2 aims to improve manufacturing processes for clinical trial products, which struggle with long lead times and are often ill-suited to adaptive clinical trial supply. An automated clinical bottle packing line has been created that can be linked to a qualified person dashboard for real-time batch release, enabling just-in-time product packing and smart labelling. This will reduce material waste, cost and environmental footprint and give patients faster and cheaper clinical trial medicines.
Grand Challenge 3
Grand Challenge 3 is revolutionising how oligonucleotides are manufactured. It will help overcome barriers to the scalable, affordable, and sustainable manufacture of this promising next-generation class of medicine, which has the potential to treat a wide range of diseases.
Digital Membership
Digital Membership helps the pharma industry to adapt and embrace digital transformation, including using digital manufacturing solutions such as robotics and AI. Our digital membership aids this transition and supports the industry to reduce costs, increase sustainability and, most importantly, improve patient outcomes.
